A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Ronald W. Takvorian(Massachusetts General Hospital), Ephraim P. Hochberg(Massachusetts General Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Danielle M. Brander(Duke University), Haesook T. Kim(Dana-Farber Cancer Institute), Karen Francoeur(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), David C. Fisher(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Jeremy S. Abramson(Massachusetts General Hospital), Alexandra Savell(Dana-Farber Cancer Institute), Jad Bsat(Dana-Farber Cancer Institute)
Cited by 10
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890